

9 February 2010 EMA/CVMP/64865/2010 Veterinary Medicines and Product Data Management

Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents January 2010

The CVMP Monthly Report includes statistical data for the current and previous two years on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

Scientific Advice Requests						
	95-07	2008	2009	2010	Total	
Submitted	58	5	11	3	77	

Initial Evaluation					
	95-07	2008	2009	2010	Total
Full	97	13	14	0	124
Abridged/	7	3	1	0	11
Generics					
Withdrawals	11	1	0	0	12
Positive	78	13	13	0	104
Opinions					
Negative	1	0	0	0	1
Opinions					

Marketing Authorisations					
95-07 2008 2009 2010 Total					
Granted	75	13	12	3	103
Withdrawals	1	0	1	0	2
Not renewed	2	0	0	0	2

Extensions - Annex II Applications					
	95-07	2008	2009	2010	Total
Submitted	56	4	12	0	72
Withdrawals	1	1	1	0	3
Positive	33	7	7	1	48
Opinions					
Negative	0	0	0	0	0
Opinions					



Variations – Applications submitted					
95-07 2008 2009 2010 Total					
Type IA	291	23	32	3	416
Type IB	271	25	41	1	410
Type II	158	52	40	3	253
Transfers	9	2	3	0	14

Renewals					
	95-07	2008	2009	2010	Total
Submitted	43	7	18	4	72
Positive	40	8	15	1	64
Opinions					
Negative	0	0	0	0	0
Opinions					

Arbitrations and Community Referrals						
	95-07 2008 2009 2010 Total					
Referrals	27	11	9	0	47	
Submitted						
Opinions	14	6	14	0	34	
Reached						

Establishment of MRLs for new substances							
95-07 2008 2009 2010 Total							
Submitted	65	1	4	0	70		
Withdrawals	5	0	0	0	5		
Positive	52	2	2	0	56		
Opinions ¹							
Negative	6	1	0	0	7		
Opinions ²							

Extensions / Modifications/Extrapolations of MRLs						
95-07 2008 2009 2010 Total						
Submitted	96	2	2	0	100	
Withdrawals	4	0	0	0	4	
Positive	111	2	3	0	116	
Opinions ³						
Negative	6	0	0	0	6	
Opinions ⁴						
Extrapolations	45	5	0	0	50	

¹ Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits ² Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

Arbitrations and Community Referrals in 2010

Type of referral	Date of clock start / CVMP opinion	•	Product name INN
Referral under Art. 35 of Directive 2001/82/EC	11/02/2009	•	All strengths of water soluble powders and oral solutions containing doxycycline hyclate Doxycycline hyclate
Referral under Art. 35 of Directive 2001/82/EC	16/04/2009	•	Veterinary medicinal formulations containing colistin at 2 MIU/ml and intended for administration in drinking water to any food producing species Colistin sulfate
Referral under Art. 35 of Directive 2001/82/EC Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	13/05/2009 11/11/2009 (under re-examination) 12/11/2008 11/11/2009 (under re-examination)	•	Veterinary medicinal products containing quinolones or fluoroquinolones for all food- producing species Quinolones / fluoroquinolones Tildren 500 mg Tiludronic acid (as disodium salt)
Referral for arbitration – Art. 6(12) of Regulation (EC) No 1084/2003	14/10/2009	•	Porcilis PRRS Live attenuated PRRS virus strain DV
Referral for arbitration – Art. 6(12) of Regulation (EC) No 1084/2003	14/10/2009	•	Porcilis M Hyo Inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11
Referral for arbitration – Art. 34 of Directive 2001/82/EC	11/11/2009	•	Fortekor vet and associated names Benazepril hydrochloride

Guidelines and Working Documents in 2010

Joint CHMP/CVMP Quality

Reference number	Document title	Status
EMA/CHMP/CVMP/QWP/809114/	Concept paper on the revision of	Adopted for consultation,
2009	the guideline on process validation	January 2010
		(End of consultation, April
		2010)